SOPHiA GENETICS SA

Thank you, and good morning, everyone.

Good morning. My name is Dani, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Sophia Genetics second quarter 2025 earnings conference call. Please note that all lines are in listen-only mode. Following the presentation, we will conduct a question and answer session. If at any time during this call you require immediate assistance, please press star zero for the operator. This call is being recorded on Tuesday, August 5th, 2025. I would now like to turn the conference over to Kellen Sanger, Sophia Genetics Head of Strategy and Investor Relations.

You may begin. Welcome to Sophia Genetics Second Quarter 2025 Earnings Conference Call. Joining me today to discuss our results are Dr. Yurgi Kamblong, our Co-Founder and Chief Executive Officer, Ross Muecken, our Company President, and George Cardoza, our Chief Financial Officer. I'd like to remind you that management will make statements during this call that are forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated, and you should not place undue reliance on forward-looking statements. Additional information regarding these risks, uncertainties, and factors that could cause results to differ appears in the press release issued by Sophia Genetics today and in the documents and reports filed by Sophia Genetics from time to time with the Securities and Exchange Commission. During this call, we will present both IFRS and non-IFRS financial measures. A reconciliation of IFRS to non-IFRS measures is included in today's earnings press release, which is available on our website. With that, I'll now turn the call over to Yergi.